Skip to main content

Table 1 Table 1

From: Reduction in oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma receiving omalizumab in a real-world setting

  Baseline N=916 12 months N=734 24 months N=643
Patients on OCS maintenance monotherapy, n (%) 262 (28.6) 118 (16.1) 91 (14.2)
Mean (SD) total daily OCS dose*, mg 15.49 (14.01)a 7.68 (10.94)b 5.77 (8.89)c
Mean (SD) reduction from baseline in total daily dose, mg - 7.89 (13.77)b 9.95 (15.58)c
Patients with alteration in total OCS dose, n (%)    
discontinuation - 77 (40.7)b 82 (48.8)c
reduction - 31 (16.4)b 34 (20.2)c
no change - 76 (40.2)b 48 (28.6)c
increased - 5 (2.6)b 4 (2.4)c
Mean (SD) time to either reduction or discontinuation of OCS, days - 198.5 (114.29)d 291.2 (210.86)e
  1. * OCS dose was reported in prednisolone equivalent dose as mg per day. OCS oral corticosteroid; SD standard deviation; n number of patients who received OCS at baseline and who provided OCS information at 12 months and 24 months (an=246; bn=189; cn=168; dn=108; en=116).